BioSpace News Archive

Globe Life Inc. (NYSE: GL) will release Fourth Quarter 2020 earnings after the market closes on Tuesday, February 2, 2021

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 issued in September 2019

Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary Shares (“ADSs”), in the United States for trading on The Nasdaq Global Select Market in the United States (the “U.S. Offering”)

Envista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its fourth quarter 2020 on Wednesday, February 10, 2021.

Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and full-year 2020 financial performance in a press release before the market opens on Tuesday, February 23, 2021 and to host an earnings call

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced it has entered into a collaboration with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety, and efficacy of multiple treatments with Soliton’s Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars

New Zebra EC5x series provides sleek yet durable smartphone-style design with an enriched software suite, enabling greater collaboration, individual performance and productivity

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for VLX-1005 for the treatment of heparin induced thrombocytopenia (HIT). “We are pleased the FDA has granted Orphan Drug Des

Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol ® Cyclo™, at WORLD Symposium 2021

Statistically Significant and Clinically Meaningful 52% Reduction in Opioid Consumption After Discharge Through Two Weeks Following Surgery *** Early Reductions in Pain at Rest and Pain with Activity Lasted Continuously Through Two Weeks